The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

A class of drugs called NMDA (N-methyl-D-aspartate) receptor antagonists may be an option for people with MDD who don’t feel better with conventional antidepressant treatment. Research shows ...

Company enters into option agreement with NeurOp to in-license novel GluN2B antagonists – Compounds include a highly potent and selective Phase 1-complete candidate and seven preclinical candidates – ...

NMDA (short for N-methyl-D-aspartate) receptor antagonists are a class of drugs that may help treat Alzheimer's disease, which causes memory loss, brain damage, and, eventually, death. There's no ...

A research team has identified a molecular mechanism that coordinates the operation of the N-methyl-D-aspartate (NMDA) glutamate receptor, which is key to regulating excitatory synapse function in ...

is an NMDA receptor blocker. This work has been made possible thanks to the financial support provided by the Health Research Fund, co-funded by the European Regional Development Fund (ERDF ...

Dextromethorphan-bupropion is an oral N-methyl D-aspartate (NMDA) receptor antagonist, and "represents the first new oral non-monoamine-based mechanism of action approved to treat major depressive ...

Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic. However, in recent years, some doctors have prescribed ketamine to treat ...

REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker. The investigational treatment is administered orally once daily and is designed to target hyperactive GluN1-GluN2D NMDAR ...

Thirteen percent of patients with definite anti-N-methyl-D-aspartate receptor encephalitis (ANMDARE) have suicidal thoughts and behaviors during the acute phase of the disease, according to a ...